Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA2 | P16389 | 1/20 | 0.39 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757808 | 0.89 | PDE4D (0.45) | KCNA2KCNA5KCNA1KCNA3PDE4D | |
| SCHEMBL3752069 | 0.86 | KCNA3 (0.38) | KCNA3LMNAPDE4DCNR1CNR2 | |
| SCHEMBL3754173 | 0.82 | KCNA3 (0.35) | KCNA2KCNA4KCNA5KCNA1KCNH2 | |
| SCHEMBL3754114 | 0.80 | KCNA3 (0.41) | KCNA3LMNAGAA | |
| SCHEMBL9972731 | 0.79 | ALDH1A1 (0.43) | CNR1CNR2 | |
| SCHEMBL3756873 | 0.79 | MEN1 (0.42) | — | |
| SCHEMBL3757791 | 0.79 | MET (0.41) | CNR1CNR2 | |
| SCHEMBL3421814 | 0.77 | PTGS1 (0.35) | PDE4DGAACNR1CNR2 | |
| SCHEMBL3615123 | 0.76 | KCNA3 (0.51) | KCNA2KCNA4KCNA5KCNA1KCNH2 | |
| SCHEMBL9972730 | 0.75 | SMN1; SMN2 (0.44) | KCNA3GAACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| WO-2009043117-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNH3 | KCNA2 27/4885KCNA4 28/4885KCNA5 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.